The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.

Li LiuJiangtu HeGuifeng SunNan HuangZhixuan BianChang XuYue ZhangZhongqi CuiWenqiang XuFenyong SunChengle ZhuangQiuhong ManSong Gu

Published in: Clinical and translational medicine (2022)

Our findings demonstrated that the METTL3-mediated SLC7A11 m6A modification enhances HB ferroptosis resistance. The METTL3/IGF2BP1/m6A modification promotes SLC7A11 mRNA stability and upregulates its expression by inhibiting the deadenylation process. Our study highlights a critical role of the m6A modification in SLC7A11-mediated ferroptosis, providing a potential strategy for HB therapy through blockade of the m6A-SLC7A11 axis.

Keyphrases

cell death
binding protein
signaling pathway
poor prognosis
stem cells
human health
cell therapy
growth hormone